logo

Puma Biotechnology Inc. (PBYI)



Trade PBYI now with
  Date
  Headline
4/1/2019 8:11:39 AM Puma Biotechnology And Pierre Fabre Enter Exclusive License Agreement
2/4/2019 9:57:02 PM Puma Biotechnology Announces Litigation Victory With Jury’s Decision
1/11/2019 8:10:39 AM Puma Biotechnology Enters Exclusive License Agreement With Knight Therapeutics
9/4/2018 8:16:33 AM EU Oks Puma NERLYNX For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
6/29/2018 7:35:14 AM Puma Biotechnology Gets Positive CHMP Opinion Recommending Approval Of NERLYNX
6/26/2018 8:59:51 AM Puma Biotechnology Reports Results Of CHMP Reexamination Of MAA For Neratinib
6/26/2018 8:56:30 AM Puma Biotechnology, Trading Halted Expected To Resume At 9:15 AM ET
6/18/2018 8:35:05 AM Champions Oncology Partners With Puma And NSABP Foundation On Metastatic Breast, Colon Cancer Co-clinical PDX Studies
6/2/2018 11:39:32 AM Puma Biotechnology Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With T-DM1
4/3/2018 8:46:08 AM Puma And Pint Pharma Enter Into Licensing Agreement To Commercialize NERLYNX In Latin America
3/2/2018 7:18:36 AM RBC Capital Markets Is Cutting Puma Biotechnology Inc. (PBYI) FY20 Rev. Estimate To 1032 M From 1072 M
3/2/2018 7:18:25 AM RBC Capital Markets Is Increasing Puma Biotechnology Inc. (PBYI) FY19 Rev. Estimate To 565.9 M From 561.3 M